

# Food and Drug Regulation



# Food and Drug Regulation: A Statutory Approach

Adam I. Muchmore

PROFESSOR OF LAW  
PENN STATE LAW  
UNIVERSITY PARK, PA



CAROLINA ACADEMIC PRESS  
Durham, North Carolina

Copyright © 2021  
Carolina Academic Press, LLC  
All Rights Reserved

ISBN 978-1-5310-0445-3  
e-ISBN 978-1-5310-0446-0  
LCCN 2020947321

Carolina Academic Press  
700 Kent Street  
Durham, North Carolina 27701  
Telephone (919) 489-7486  
Fax (919) 493-5668  
[www.cap-press.com](http://www.cap-press.com)

Printed in the United States of America

*To my parents*



# Summary of Contents

---

---

Part One • Agency Structure, Product Categories, and Administrative Procedure	1
Chapter 1 • Agency Structure and Product Categories	3
Chapter 2 • Administrative Procedure	39
Part Two • Research, Marketing Authorization, and Background Requirements	65
Chapter 3 • Regulation of Research	67
Chapter 4 • Marketing Authorization	81
Chapter 5 • Background Requirements	141
Part Three • FFDCa Chapter IV Products—Food, Food Additives, and Dietary Supplements	165
Chapter 6 • Food	167
Chapter 7 • Food Additives	227
Chapter 8 • Dietary Supplements	245
Chapter 9 • Label Claims for Food and Dietary Supplements	271
Part Four • FFDCa Chapter V Products—Drugs, Animal Drugs, Devices, and Combination Products	303
Chapter 10 • Drugs	305
Chapter 11 • Animal Drugs	395
Chapter 12 • Medical Devices	407
Chapter 13 • Combination Products	439
Part Five • PHSA Products—Biologics and HCT/Ps	453
Chapter 14 • Biologics	455
Chapter 15 • Human Cells, Tissues, and Cellular and Tissue-Based Products	475
Part Six • FFDCa Chapter VI, VII, and IX Products—Cosmetics, Color Additives, and Tobacco Products	493
Chapter 16 • Cosmetics	495
Chapter 17 • Color Additives	507
Chapter 18 • Tobacco Products	529
Part Seven • FDA Enforcement, Federal Preemption, and Regulation of Imports	571
Chapter 19 • FDA Enforcement	573
Chapter 20 • Federal Preemption	601
Chapter 21 • Regulation of Imports	657
Part Eight • Appendices	669
Appendix A • Timeline of All Key Statutes in Casebook	671
Appendix B • Further Reading	677





# Contents

---

---

List of Tables	xxi
Table of Cases	xxv
Table of Principal Cases	xxix
Table of Principal Federal Register Documents	xxxi
Table of Principal Guidance Documents	xxxiii
Acknowledgments	xxxv
Preface—About This Book	xxxvii
Structure of the Book	xxxviii
Citation Format and Editorial Approach	xxxix

PART ONE • AGENCY STRUCTURE, PRODUCT CATEGORIES,  
AND ADMINISTRATIVE PROCEDURE

<b>Chapter 1 • Agency Structure and Product Categories</b>	<b>3</b>
A. Introduction	3
1. Introduction to This Casebook	3
Primary Document Types	3
Where to Find the Different Document Types	5
Structure of Individual Chapters	6
The Relationship Between Codified and Uncodified Material (and Why It Is Necessary to Study Both)	7
The Relationship Between Food and Drug Regulation and Administrative Law	8
2. Introduction to This Chapter	8
B. Outline of Regulatory Regime	10
C. Historical Context	12
1. Organizational History	12
FDA Website, History of FDA’s Internal Organization: Brief Organizational History	12
2. FDA’s “Milestones” List	13
FDA Website, Milestones in U.S. Food and Drug Law History	13
D. Product Categories	29
1. Categorization Problems	30
<i>United States v. An Article of Drug . . . Bacto-Unidisk . . .</i>	30
E. Key Points	37

<b>Chapter 2 • Administrative Procedure</b>	<b>39</b>
A. Introduction	39
B. Outline of Regulatory Regime	39
C. Agency Statutory Interpretation—Generally	41
<i>Chevron, U.S.A., Inc. v. Natural Res. Def. Council, Inc.</i>	42
D. FDA’s Rulemaking Authority	47
<i>Abbott Labs. v. Gardner</i>	48
<i>Nat’l Ass’n of Pharm. Mfrs. v. FDA</i>	54
E. The Role of Guidance Documents	62
F. Key Points	64

PART TWO • RESEARCH, MARKETING AUTHORIZATION,  
AND BACKGROUND REQUIREMENTS

<b>Chapter 3 • Regulation of Research</b>	<b>67</b>
A. Introduction	67
B. Outline of Regulatory Regime	68
C. Research on Human Subjects	69
1. The Belmont Report	69
1979-04-18 Dept. of Health, Education, and Welfare Notice, Protection of Human Subjects	69
2. FDA Implementation of the Belmont Report	73
a. Informed Consent	73
1979-08-14 FDA Proposed Rule, Informed Consent	74
b. Prisoners as Research Subjects	78
1980-05-30 FDA Final Rule, Protection of Human Subjects; Prisoners Used as Subjects in Research	78
D. Key Points	79
<b>Chapter 4 • Marketing Authorization</b>	<b>81</b>
A. Introduction	81
B. Outline of Regulatory Regime	83
C. The Trade-Off Between Rigorous Marketing Authorization Requirements and Availability of Useful Products	86
<i>Abigail Alliance v. Von Eschenbach</i>	86
D. Standards for Marketing Authorization	93
E. Pathways to Market: Generally	93
F. Pathways to Market: Therapeutic Products	97
1. Paradigm Pathways	97
2. Alternate Pathways	99
a. Abbreviated Pathways	99
b. Accelerated Pathways	100
c. Human Efficacy Studies Not Ethical or Feasible (Animal Rule)	101
d. Premarket Notification/510(k) Pathway	102
e. Determination that a Drug or Device Falls into a Subset for which No Marketing Authorization Is Required	103

f. Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)	105
g. Exemption from Efficacy Requirement (Humanitarian Device Exemption)	106
h. Conditional Approval (Animal Drugs Only)	106
i. Indexing (Animal Drugs Only)	107
G. Pathways to Market: Nontherapeutic Products	107
1. Safety Only	107
a. Paradigm Pathways	108
b. Alternate pathways	109
2. Protection of the Public Health	110
a. Paradigm Pathway	111
b. Alternate Pathways	112
H. No Marketing Authorization Required: Therapeutic and Nontherapeutic Products	113
1. Products Not Subject to Any Marketing Authorization Requirement	113
2. Products Exempted from Otherwise-Applicable Marketing Authorization Requirements	114
I. The Designations	115
1. Description	115
a. Review Clock Designations	115
b. Review Assistance Designations	117
c. Market Exclusivity Designations	119
FDA Website, Frequently Asked Questions on Patents and Exclusivity	119
2. Example: Use of the Designations	122
2019-12-19 FDA News Release, First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response	122
J. Related Area Involving Extensive Interaction with Other Agencies: Medical Countermeasures	124
K. Access Before Marketing Authorization	125
1. Standard Investigational Use	125
1987-03-19 FDA Final Rule, New Drug, Antibiotic, and Biologic Drug Product Regulations	126
2. Expanded Access	131
2009-08-13 FDA Final Rule, Expanded Access to Investigational Drugs for Treatment Use	132
3. Emergency Use	133
2020-03-28 Emergency Use Authorization for Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease	134
2020-06-15 FDA Letter Revoking Emergency Use Authorization for Chloroquine Phosphate and Hydroxychloroquine Sulfate	137
4. The “Right to Try” Act	138

L. Key Points	139
<b>Chapter 5 • Background Requirements</b>	<b>141</b>
A. Introduction	141
B. Outline of Regulatory Regime	141
C. The Five Sets of Background Requirements	141
1. Prohibition of Adulteration: Production-Process Requirements (Good Manufacturing Practices, Hazard Analysis, and Related Product Standards)	141
a. Overview	141
b. Outline of Regulatory Regime	144
2015-09-17 FDA Final Rule, Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food	147
2. Prohibition of Misbranding: Labeling Requirements	152
a. Overview	152
b. Outline of Regulatory Regime	152
3. Establishment Registration	155
a. Overview	155
b. Outline of Regulatory Regime	155
4. User Fees	157
a. Overview	157
b. Outline of Regulatory Regime	157
Congressional Research Service, FDA Human Medical Product User Fee Programs: In Brief	158
5. Postmarket Requirements	159
a. Overview	159
b. Outline of Regulatory Regime	160
D. Key Points	162

PART THREE • FFDCA CHAPTER IV PRODUCTS — FOOD,  
FOOD ADDITIVES, AND DIETARY SUPPLEMENTS

<b>Chapter 6 • Food</b>	<b>167</b>
A. Introduction	167
B. Outline of Regulatory Regime	167
C. Adulteration	170
<i>United States v. 298 Cases, etc., Ski Slide Brand Asparagus, etc.</i>	170
D. Misbranding	171
<i>United States v. Ninety-five Barrels (More or Less) Alleged     Apple Cider Vinegar</i>	171
<i>United States v. 24 Bottles . . . Sterling Vinegar and Honey</i>	174
E. Standardized, Imitation, and Nonstandardized Food	176
<i>Federal Security Adm'r v. Quaker Oats Co.</i>	176
<i>62 Cases . . . Jam v. United States</i>	183
F. Related Areas Not Regulated Primarily by FDA	187
1. Meat, Eggs, Poultry, and Fish of the Order Siluriformes	187

a. Outline of Regulatory Regime	187
2015-12-02 USDA FSIS Final Rule, Mandatory Inspection of Fish of the Order Siluriformes and Products Derived from Such Fish	195
2. Alcohol	197
a. Outline of Regulatory Regime	197
FDA-ATF, Memorandum of Understanding between the Food and Drug Administration and the Bureau of Alcohol, Tobacco and Firearms	199
<i>Granholm v. Heald</i>	202
3. Agricultural Biotechnology	215
a. Outline of Regulatory Regime	216
1986-06-26 OSTP Policy Announcement, Coordinated Framework for the Regulation of Biotechnology	217
b. Biotechnology Labeling and Required Speech	219
<i>Int'l Dairy Foods Ass'n v. Amestoy</i>	219
USDA Website, How the Federal Government Regulates Biotech Plants	223
G. Key Points	225
<b>Chapter 7 • Food Additives</b>	<b>227</b>
A. Introduction	227
B. Outline of Regulatory Regime	227
C. The Food Additives Delaney Clause	229
<i>Les v. Reilly</i>	229
D. GRAS Presumption for Proteins Produced through Genetic Engineering	234
<i>Alliance for Bio-Integrity v. Shalala</i>	234
E. Cannabidiol (CBD)	240
2019-11-25 FDA Press Release re: Cannabidiol (CBD)	240
F. Key Points	243
<b>Chapter 8 • Dietary Supplements</b>	<b>245</b>
A. Introduction	245
B. Outline of Regulatory Regime	245
C. FDA's Pre-DSHEA Effort to Regulate Vitamin and Mineral Supplements	246
<i>Nat'l Nutr. Foods Ass'n v. Mathews</i>	247
<i>Nat'l Nutr. Foods Ass'n v. Kennedy</i>	249
1979-03-16 FDA Final Order, Vitamin and Mineral Products; Revocation of Regulations	256
D. The Dietary Supplement Health and Education Act (DSHEA) of 1994	256
Senate Report No. 103-410, Oct. 8, 1994	257
E. The Congressional Findings of Fact	258
Dietary Supplement Health and Education Act of 1994	259
F. The Statutory Changes Brought About by DSHEA	260

G. FDA Implementation of DSHEA	262
1. New Dietary Ingredient Notification	262
1997-09-23 FDA Final Rule, Premarket Notification for New Dietary Ingredients	262
Statement by Jane E. Henney, M.D., Commissioner Food and Drug Administration, Before the Committee on Government Reform, U.S. House of Representatives	266
H. Key Points	268
<b>Chapter 9 • Label Claims for Food and Dietary Supplements</b>	<b>271</b>
A. Introduction	271
B. Outline of Regulatory Regime	272
C. The Five Primary Types of Label Claims	274
D. Label Claims and Commercial Speech	277
1. The Commercial Speech Doctrine Generally	277
<i>Cent. Hudson Gas &amp; Electric Co. v. Pub. Serv. Comm'n of N.Y.</i>	277
2. Litigation Over Dietary Supplement Label Claims	281
<i>Pearson v. Shalala</i>	281
<i>Whitaker v. Thompson</i>	290
E. FDA Label-Claim Guidance	295
FDA, Guidance for Industry: FDA's Implementation of Qualified Health Claims (May 2006)	295
FDA, Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims (Jan. 2009)	298
F. Key Points	300
PART FOUR • FFDCA CHAPTER V PRODUCTS — DRUGS, ANIMAL DRUGS, DEVICES, AND COMBINATION PRODUCTS	
<b>Chapter 10 • Drugs</b>	<b>305</b>
A. Introduction	305
B. Outline of Regulatory Regime	305
C. Drug Regulation under the 1906 Statute	310
<i>United States v. Johnson</i>	310
1. The Sherley Amendment	318
D. Drug Regulation under the FFDCA of 1938	318
1. The Kefauver-Harris Amendments of 1962	319
2. FDA Implementation of the Kefauver-Harris Amendments	320
1966-07-09 FDA Notice, Reports of Information for Drug Effectiveness	320
1970-05-08 FDA Final Rule, Hearing Regulations and Regulations Describing Scientific Content of Adequate and Well-Controlled Clinical Investigations	321
3. Current Text of Some Key Regulations from Kefauver-Harris Implementation	324
4. Judicial Review of FDA's Kefauver-Harris Implementation	324
a. The 1973 Quartet	324

<i>Weinberger v. Hynson, Westcott &amp; Dunning, Inc.</i>	325
<i>Weinberger v. Bentax Pharm., Inc.</i>	336
b. “Me-Too” Drugs, the Hatch-Waxman Act, and the Generic Drug Industry	339
<i>Hoffman-LaRoche, Inc. v. Weinberger</i>	340
<i>United States v. Generix Drug Corp.</i>	343
<i>FTC v. Actavis, Inc.</i>	346
E. Additional Issues	359
1. Over the Counter (OTC) Drugs	359
1972-01-05 FDA Proposed Rule, Proposal Establishing Rule-Making Procedures for Classification [of OTC Drugs]	359
2020-3-30 FDA Press Release on the Signing of the CARES Act	363
2. On-Label and Off-Label Use	363
<i>United States v. Caronia</i>	364
3. The Rise of Large-Molecule Biologic Drugs	380
FDA Website, Frequently Asked Questions About Therapeutic Biological Products	380
4. Compounded Drugs	383
FDA Website, Compounding Laws and Policies	383
F. Related Area Not Regulated Primarily by FDA: Federally Controlled Substances	384
1. Controlled Substances	384
<i>Gonzales v. Raich</i>	384
G. Key Points	393
<b>Chapter 11 • Animal Drugs</b>	<b>395</b>
A. Introduction	395
B. Outline of Regulatory Regime	395
C. Overview	397
FDA Website, FDA Regulation of Animal Drugs	397
D. Related Area Not Regulated Primarily by FDA—Veterinary Biologics	401
1. Outline of Regulatory Regime	402
2. Overview	403
USDA, Veterinary Biologics: Use and Regulation	403
E. Key Points	405
<b>Chapter 12 • Medical Devices</b>	<b>407</b>
A. Introduction	407
B. Outline of Regulatory Regime	407
C. Device Misbranding	411
<i>United States v. An Article . . . Acu-Dot . . .</i>	411
D. Medical Device Classification and Review	413
<i>United States v. An Article of Drug . . . Bacto-Unidisk . . .</i>	413
1992-04-28 FDA Interim Rule, Medical Devices; Substantial Equivalence; 510(k) Summaries and 510(k) Statements; Class III Summaries; Confidentiality of Information	414

<i>Medtronic, Inc. v. Lohr</i>	418
Judith A. Johnson, <i>Congressional Research Service, FDA Regulation of Medical Devices</i>	421
FDA, Guidance for Industry and FDA Staff: De Novo Classification Process (Evaluation of Automatic Class III Designation) (Oct. 2017)	424
E. Medical Devices and the 2020 Novel Coronavirus	425
FDA, Guidance for Industry and FDA Staff: Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Mar. 2020)	425
FDA, Guidance for Industry and FDA Staff: Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Mar. 2020)	431
F. Animal Devices	436
FDA Website, How FDA Regulates Animal Devices	436
G. Key Points	437
<b>Chapter 13 • Combination Products</b>	<b>439</b>
A. Introduction	439
B. Outline of Regulatory Regime	439
C. Overview	440
1991-11-21 FDA Final Rule, Assignment of Agency Component for Review of Premarket Applications	440
2013-01-22 FDA Final Rule, Current Good Manufacturing Practice Requirements for Combination Products	444
2016-12-20 Final Rule, Postmarket Safety Reporting for Combination Products	449
2017-01-09 FDA Final Rule, Clarification of When Products Made or Derived from Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding “Intended Uses”	451
D. Key Points	452
<b>PART FIVE • PHSA PRODUCTS — BIOLOGICS AND HCT/PS</b>	
<b>Chapter 14 • Biologics</b>	<b>455</b>
A. Introduction	455
B. Outline of Regulatory Regime	455
C. Historical Context	457
FDA, Science and the Regulation of Biological Products: From a Rich History to a Challenging Future— Commemorating 100 Years of Biologics Regulation	457
1972-06-29 Public Health Service and FDA Notice, Statement of Organization, Functions, and Delegations of Authority	459



1972-08-18 FDA Proposed Rule, Procedures for Review of Safety, Effectiveness, and Labeling	460
1982-06-22 FDA Notice, Statement of Organization, Functions, and Delegations of Authority	462
1987-10-15 FDA Notice, Statement of Organization, Functions, and Delegations of Authority	463
1999-10-20 FDA Final Rule, Biological Products Regulated Under Section 351 of the Public Health Service Act; Implementation of Biologics License; Elimination of Establishment License and Product License	463
2003-06-26 FDA Notice, Drug and Biological Product Consolidation	465
FDA Website, Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Research	466
2020-03-23 FDA Press Release, Insulin Gains New Pathway to Increased Competition	468
D. Biologics and the 2020 Novel Coronavirus	469
FDA, Guidance for Industry: Investigational COVID-19 Convalescent Plasma (April 2020)	469
E. Related Area Not Regulated Primarily by FDA: Veterinary Biologics	472
F. Key Points	472
<b>Chapter 15 • Human Cells, Tissues, and Cellular and Tissue-Based Products</b>	<b>475</b>
A. Introduction	475
B. Outline of Regulatory Regime	476
C. FDA's Implementation of Human Tissue Regulation	476
1997-07-29 FDA Final Rule, Human Tissue Intended for Transplantation	476
2001-01-19 Final Rule, Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Regulation and Listing	479
2004-11-24 FDA Final Rule, Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement	482
D. Related Area Not Regulated Primarily by FDA—Organ Transplantation	485
1998-04-02 HHS Final Rule, Organ Procurement and Transplantation Network	485
E. Key Points	491
 <b>PART SIX • FFDCA CHAPTER VI, VII, AND IX PRODUCTS— COSMETICS, COLOR ADDITIVES, AND TOBACCO PRODUCTS</b>	
<b>Chapter 16 • Cosmetics</b>	<b>495</b>
A. Introduction	495
B. Outline of Regulatory Regime	496

C. The Distinction between Drugs and Cosmetics	497
<i>United States v. An Article . . . Sudden Change</i>	497
2011-04-15 FDA Warning Letter to Lifetech Resources	501
D. Key Points	506
<b>Chapter 17 • Color Additives</b>	<b>507</b>
A. Introduction	507
B. Outline of Regulatory Regime	507
C. Whether Cosmetics Are Color Additives	508
<i>Toilet Goods Ass’n v. Finch</i>	509
D. Overview and Historical Context	514
FDA, Guidance for Industry: Color Additive Petitions—FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices (Jul. 2009)	514
E. The Color Additives “Delaney Clause”	517
<i>Pub. Citizen v. Young</i>	517
F. Key Points	528
<b>Chapter 18 • Tobacco Products</b>	<b>529</b>
A. Introduction	529
B. Outline of Regulatory Regime	529
C. Nonregulation: 1906–2009	530
Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (1964)	531
<i>FDA v. Brown &amp; Williamson Tobacco Corp.</i>	533
D. 2009–Present: Regulation Under the Tobacco Control Act	545
Tobacco Control Act: Findings of Fact	545
Tobacco Control Act: Statement of Purpose	546
1. Basic Statutory and Regulatory Provisions	547
2. Types of Tobacco Products Subject to FDA Authority	548
3. Developing a Regulatory Regime: Non-Electronic Tobacco Products	548
a. Reducing Use by Children and Adolescents	548
2010-03-19 FDA Final Rule, Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents	549
b. Substantial equivalence	550
2011-01-06 FDA Proposed Rule, Tobacco Products, Exemptions from Substantial Equivalence Requirements	550
2011-07-05 FDA Final Rule, Tobacco Products, Exemptions from Substantial Equivalence Requirements	552
c. The Tobacco Deeming Rule	553
2016-05-10 FDA Final Rule, Deeming Tobacco Products to Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act	554

4. Developing a Regulatory Regime: Electronic Nicotine Delivery Systems (ENDS)	560
a. The Decision to Deem ENDS Products	560
2016-05-10 FDA Final Rule, Deeming Tobacco Products to Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act	560
b. The Implications of the ENDS Deeming Decision for Vape Shops	561
2016-05-10 FDA Final Rule, Deeming Tobacco Products to Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act	562
c. THC Vaping	567
Press Release, FDA, Statement on Consumer Warning to Stop Using THC Vaping Products Amid Ongoing Investigation Into Lung Illnesses (Oct. 4, 2019)	567
E. Key Points	570

PART SEVEN • FDA ENFORCEMENT, FEDERAL PREEMPTION,  
AND REGULATION OF IMPORTS

<b>Chapter 19 • FDA Enforcement</b>	<b>573</b>
A. Introduction	573
1. Chapter III Enforcement Provisions	573
2. Chapter VII Enforcement Provisions	575
B. Outline of Regulatory Regime	576
C. Enforcement Discretion	578
<i>Heckler v. Chaney</i>	578
1. Advisory Actions	587
a. Untitled Letters	587
FDA Regulatory Procedures Manual § 4-2-1. Format and Content [of Untitled Letters]	587
b. Warning Letters	588
FDA Regulatory Procedures Manual § 4-1-1. Warning Letter Procedures	588
FDA Regulatory Procedures Manual § 4-1-10. Warning Letter Format	590
FDA Regulatory Procedures Manual § 4-1-8. Warning Letter Follow-Up	591
D. <i>Mens Rea</i> for FFDCA Violations	592
<i>United States v. Park</i>	592
E. Key Points	599
<b>Chapter 20 • Federal Preemption</b>	<b>601</b>
A. Introduction	601
B. Outline of Regulatory Regime	604

C. Cases	605
<i>Hillsborough Cnty. v. Automated Med. Labs., Inc.</i>	605
<i>Reigel v. Medtronic, Inc.</i>	611
<i>Wyeth v. Levine</i>	618
<i>Bruesewitz v. Wyeth LLC</i>	632
<i>Merck Sharp &amp; Dohme Corp. v. Albrecht</i>	644
D. Key Points	655
<b>Chapter 21 • Regulation of Imports</b>	<b>657</b>
A. Introduction	657
B. Outline of Regulatory Regime	659
1998-11-06 FDA Final Rule, Mutual Recognition of Pharmaceutical Good Manufacturing Practice Inspection Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports Between the United States and the European Community	660
2015-11-27 FDA Final Rule, Foreign Supplier Verification Programs for Importers of Food for Humans and Animals	661
2015-11-27 FDA Final Rule, Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications	666
C. Key Points	668

## PART EIGHT • APPENDICES

<b>Appendix A • Timeline of All Key Statutes in Casebook</b>	<b>671</b>
<b>Appendix B • Further Reading</b>	<b>677</b>
A. Casebooks and Treatises	677
B. Food and Drug Regulation Generally (Other Than Casebooks and Treatises)	677
C. Administrative Practice and Procedure	678
D. Food	678
E. Food Additives	678
F. Dietary Supplements	678
G. Food and Drug Classics (Including “Muckraking”)	678
H. Drugs and Biologics	679
I. Medical Devices	680
J. Medicine Generally	680
K. The Microbiome	680
L. Tobacco Products	680
M. Cancer / Carcinogen Regulation	680
N. Statutory Interpretation and Administrative Law	680
<b>Index</b>	<b>681</b>

# List of Tables

---

---

The Relationship between Codified and Calendar-Based Materials	5
Timeline of Key Statutes: FDA Structure	10
Timeline of Key Statutes: Product Categories	10
Key Statutory Provisions: FDA Structure	11
Key Statutory Provisions: Product Categories	11
Key Statutory Provisions: Adulteration and Misbranding	11
Key Regulatory Provisions: FFDCA Structure	12
Key Regulatory Provisions: Product Categories	12
Timeline of Key Statutes: Administrative Procedure	40
Key Statutory Provisions: Administrative Procedure Generally	40
Key Statutory Provisions: Administrative Procedure at FDA	40
Key Regulatory Provisions: Administrative Procedure at FDA	41
FDA Guidance Documents as of September 6, 2020	63
Timeline of Key Statutes: Regulation of Research	68
Key Statutory Provisions: Regulation of Research	68
Key Regulatory Provisions: Regulation of Research	69
Timeline of Key Statutes: Marketing Authorization	83
Marketing Authorization: Standards and Pathways	96
21 C.F.R. Part 117, Subpart B—Current Good Manufacturing Practice	143
21 C.F.R. Part 117, Subpart C—Hazard Analysis and Risk-Based Preventive Controls	143
Timeline of Key Statutes: Production-Process Requirements	144
Key Statutory Provisions: Production-Process Requirements	144
Key Regulatory Provisions: Broadly Applicable Production-Process Requirements	145
Key Regulatory Provisions: Subcategory-Specific Production-Process Requirements	146
Timeline of Key Statutes: Labeling	153
Key Statutory Provisions: Labeling	153
Key Regulatory Provisions: Labeling	154
Timeline of Key Statutes: Establishment Registration	155
Key Statutory Provisions: Establishment Registration	156
Key Regulatory Provisions: Establishment Registration	156
Timeline of Key Statutes: User Fees	157
Timeline of Key Statutes: Postmarket Requirements	160

Key Statutory Provisions: Postmarket Requirements	160
Key Regulatory Provisions: Postmarket Requirements	161
Timeline of Key Statutes: Food	167
Key Statutory Provisions: Food	168
Key Regulatory Provisions: Food Generally	169
Key Regulatory Provisions: Food Standards	169
Timeline of Key Statutes: USDA Inspection of Meat, Eggs, Poultry, and Fish of the Order Siluriformes	187
Key Statutory Provisions: Federal Meat Inspection Act	188
Key Statutory Provisions: Poultry Products Inspection Act	190
Key Statutory Provisions: Egg Products Inspection Act	191
Key Regulatory Provisions: Meat and Poultry Inspection	192
Key Regulatory Provisions: Meat and Poultry Regulatory Requirements	193
Key Regulatory Provisions: Fish of the Order Siluriformes	194
Key Regulatory Provisions: Poultry Products Inspection	195
Key Regulatory Provisions: Egg Products Inspection	195
Timeline of Key Statutes: Alcohol Regulation	197
Key Statutory Provisions: Alcohol Regulation	197
Key Regulatory Provisions: Alcohol Regulations Administered by Treasury	198
Timeline of Key Statutes: Agricultural Biotechnology	216
Key Statutory Provisions: Agricultural Biotechnology	216
Key Regulatory Provisions: Agricultural Biotechnology	216
Timeline of Key Statutes: Food Additives	227
Key Statutory Provisions: Food Additives	227
Key Regulatory Provisions: Food Additives (Other Than Regulations Authorizing Particular Substances)	228
Key Regulatory Provisions: Regulations Authorizing Addition of Particular Substances to Food Generally	228
Key Regulatory Provisions: Regulations Authorizing Addition of Particular Substances to Animal Food	228
Timeline of Key Statutes: Dietary Supplements	245
Key Statutory Provisions: Dietary Supplements	246
Key Regulatory Provisions: Dietary Supplements	246
Timeline of Key Statutes: Label Claims	272
Key Statutory Provisions: Label Claims	272
Key Regulatory Provisions: Label Claims	272
21 C.F.R. 101, Subpart D. Specific Requirements for Nutrient Content Claims	273
21 C.F.R. 101, Subpart E. Specific Requirements for Health Claims	273
21 C.F.R. 101, Subpart F. Specific Requirements for Descriptive Claims That Are Neither Nutrient Content Claims nor Health Claims	273
The Five Primary Types of Label Claims for Conventional Foods and Dietary Supplements	275
Timeline of Key Statutes: Drugs Generally	305

Timeline of Key Statutes: Statutes Carving Out New Categories from Products Formerly Regulated as Drugs (Some of Which Still Overlap with Drugs)	306
Key Statutory Provisions: Drugs Generally	307
Key Regulatory Provisions: Drugs Generally	308
Key Regulatory Provisions: Regulations Authorizing Marketing of Particular Substances as Over-the-Counter Human Drugs (OTC Drug Monographs)	309
Timeline of Key Statutes: Animal Drugs	395
Key Statutory Provisions: Animal Drugs	395
Key Regulatory Provisions: Animal Drugs Generally	396
Key Regulatory Provisions: Lists of Approved New Animal Drugs	397
Key Regulatory Provisions: Animal Drugs in Food and Feed	397
Timeline of Key Statutes: Veterinary Biologics	402
Key Statutory Provisions: Veterinary Biologics	402
Key Regulatory Provisions: Veterinary Biologics	402
Key Regulatory Provisions: Regulations Listing Standards for Licensed Veterinary Biologics	403
Timeline of Key Statutes: Medical Devices	408
Key Statutory Provisions: Medical Devices	408
Key Regulatory Provisions: Medical Devices Generally	409
Key Regulatory Provisions: Lists of Classified Devices	410
Timeline of Key Statutes: Combination Products	439
Key Statutory Provisions: Combination Products	440
Key Regulatory Provisions: Combination Products	440
Timeline of Key Statutes Specific to Biologics	456
Key Statutory Provisions Specific to Biologics	456
Key Regulatory Provisions Specific to Biologics: Generally	456
Key Regulatory Provisions Specific to Biologics: Lists of Biological Product Standards	456
Timeline of Key Statutes: HCT/Ps	476
Key Statutory Provisions: HCT/Ps	476
Key Regulatory Provisions: HCT/Ps	476
Timeline of Key Statutes: Cosmetics	496
Key Statutory Provisions: Cosmetics	496
Key Regulatory Provisions: Cosmetics	496
Timeline of Key Statutes: Color Additives	507
Key Statutory Provisions: Color Additives	508
Key Regulatory Provisions: Color Additives Generally	508
Key Regulatory Provisions: Listed Color Additives	508
Timeline of Key Statutes: FDA Regulation of Tobacco Products	529
Key Statutory Provisions: FDA Regulation of Tobacco Products	529
Key Regulatory Provisions Administered by FDA: Tobacco Products	530
Key Regulatory Provisions Administered by Treasury: Tobacco Products	530

Key Regulatory Provisions Administered by Dept. of Justice: Tobacco Products	530
Timeline of Key Statutes: FDA Enforcement	576
Key Statutory Provisions: FDA Enforcement	577
Key Statutory Provisions: Adulteration and Misbranding	577
Key Regulatory Provisions: FDA Enforcement	578
Timeline of Key Statutes: Preemption	604
Key Statutory Provisions: Preemption	604
Key Regulatory Provisions: Preemption	604
Timeline of Key Statutes: Regulation of Imports	659
Key Statutory Provisions: Regulation of Imports	659
Key Regulatory Provisions: Regulation of Imports	660
Timeline of All Key Statutes Listed in Outline of Regulatory Regime Charts	671



# Table of Cases

---

---

References are to pages. Bold numbers indicate the page on which an excerpt of a principal case begins.

- 24 Bottles . . . Sterling Vinegar and Honey, United States v., **174**  
298 Cases, etc., Ski Slide Brand Asparagus, etc. United States v., **170**  
38 Dozen Bottles, United States v., 59  
62 Cases, More or Less, Each Containing 6 Jars of Jam v. United States, 36, **183**, 514
- Abbott Labs. v. Gardner, **48**, 55, 331, 338, 508, 579, 581, 586  
Abigail Alliance v. Von Eschenbach, **86**  
Adickes v. S. H. Kress & Co., 329  
Alabama Power Co. v. Costle, 521, 522  
Alberty Food Products Co. v. United States, 17  
Alliance for Bio-Integrity v. Shalala, 234  
American Bus. Ass'n v. United States, 236  
An Article . . . Acu-Dot . . . , United States v., **411**  
An Article . . . Sudden Change, United States v., **497**  
An Article of Drug . . . Bacto-Unidisk . . . , United States v., **30**, 413, 543
- Bacchus Imports, Ltd. v. Dias, 204  
Barnhart v. Peabody Coal Co., 635  
Bates v. State Bar of Arizona, 279  
Bell Atlantic Corp. v. Twombly, 359
- Bruesewitz v. Wyeth LLC, 603, **632**  
Cardiff, United States v., 17  
Carey v. Population Services International, 280  
Caronia, United States v., **364**  
Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n, 220, 221, **277**  
Chevron, U.S.A., Inc. v. Natural Res. Def. Council, Inc., 42, 237, 239, 527, 533, 537, 607  
Chrysler Corp. v. Brown, 61  
CIBA Corp. v. Weinberger, 56, 324  
Cipollone v. Liggett Group, Inc., 615  
Citizens to Preserve Overton Park v. Volpe, 580, 581, 584  
Consolidated Edison Co. v. Public Service Comm'n, 278  
Craig v. Boren, 208
- Del Monte Fresh Produce N.A., Inc. v. United States, 657  
District of Columbia v. Heller, 639  
Dotterweich, United States v., 16, 35, 595
- English v. General Electric Co., 602  
Ewing v. Mytinger & Casselberry, Inc., 50  
Exxon Mobil Corp. v. Allapattah Services, Inc., 639  
Far Eastern Conference v. United States, 339

- FDA v. Brown & Williamson Tobacco Corp., 26, **533**  
 Fed. Sec. Adm'r v. Quaker Oats Co., 176, 185, 500  
 Florida Lime & Avocado Growers, Inc. v. Paul, 607  
 FPC v. Texaco, 328  
 Friedman v. Rogers, 279, 286  
 FTC v. Actavis, Inc., **346**
- Gardner v. Toilet Goods, 508  
 Geier v. American Honda Motor Co., 624, 625, 626, 627  
 Generix, United States v., 343  
 Gibbons v. Ogden, 606  
 Gonzales v. Carhart, 91  
 Gonzales v. Raich, **384**  
 Granholm v. Heald, 202  
 Greenwood v. United States, 91
- Heckler v. Chaney, **578**  
 Hillsborough Cnty. v. Automated Med. Labs., Inc., 603, **605**, 624  
 Hines v. Davidowitz, 606, 607, 609, 621, 625  
 Hoffman-LaRoche, Inc. v. Weinberger, **340**  
 Hostetter v. Idlewild Bon Voyage Liquor Corp., 213
- In re (see name of party)**  
 Int'l Dairy Foods Ass'n v. Amestoy, **219**
- Jacobellis v. Ohio, 289  
 Jacobson v. Massachusetts, 91  
 Johnson, United States v., 14, **310**  
 Jones v. United States, 639
- Kansas v. Garcia, 602, 603  
 Kordel v. United States, 175
- Leary v. United States, 387  
 Les v. Reilly, **229**  
 Lexington Mill and Elevator Company, United States v., 15  
 Lottery Case (Champion v. Ames), 317
- Marshall v. Jerrico, Inc., 585  
 McDermott Int'l, Inc. v. Wilander, 642  
 Mead Corp., United States v., 625  
 Medtronic, Inc. v. Lohr, **418**, 611, 612, 615, 616, 618, 638  
 Menasche, United States v., 580  
 Merck Sharp & Dohme Corp. v. Albrecht, 602, 603, **644**  
 Monsanto Co. v. Kennedy, 523  
 Moore v. East Cleveland, 86  
 Morissette v. United States, 596  
 Morrison v. National Australia Bank, Ltd., 658  
 Morrison, United States v., 386, 392  
 Mourning v. Family Publications Service, Inc., 61  
 Mutual Pharmaceutical Co., Inc. v. Bartlett, 603
- Nat'l Ass'n of Pharm. Mfrs. v. FDA, **54**, 144  
 Nat'l Nutr. Foods Ass'n v. FDA, 55, 250  
 Nat'l Nutr. Foods Ass'n v. Kennedy, **249**  
 Nat'l Nutr. Foods Ass'n v. Mathews, **247**  
 New York v. FERC, 650  
 Ninety-five Barrels (More or Less) Alleged Apple Cider Vinegar, United States v., 15, **171**
- Oakland Cannabis Buyers' Cooperative, United States v., 388
- Pacific Bell Telephone Co. v. Linkline Communications, Inc., 357  
 Park, United States v., **592**  
 Pearson v. Shalala, **281**  
 Philadelphia v. New Jersey, 207, 211  
 Pike v. Bruce Church, Inc., 207, 211  
 Primus, In re, 280  
 Pub. Citizen v. United States Nuclear Regulatory Comm'n, 236  
 Pub. Citizen v. Young, 231, **517**  
 Pub. Health Assoc. v. Veneman, 343

- R.M.J., In re, 285  
Reigel v. Medtronic, Inc. 603, **611**  
Rice v. Santa Fe Elevator Corp., 606  
Rusk v. Cort, 48  
Rust v. Sullivan, 239  
Rutherford, United States v., 90, 91
- Scott v. Food and Drug  
Administration, 524  
Shalala v. Whitecotton, 632  
Shimer, United States v., 43  
Skidmore v. Swift & Co., 625  
Smith v. California, 596  
Sorrell v. IMS Health, Inc., 372, 374  
State Bd. of Equalization of Cal. v.  
Young's Market Co., 213  
State of Louisiana v. Mathews, 478,  
481, 483  
Storer Broadcasting Co., United  
States v., 328, 330  
Sullivan, United States v., 35, 59
- Toilet Goods Ass'n v. Finch, **509**  
Toilet Goods Assn. v. Gardner, 49  
TVA v. Hill, 47
- United States v.** (see name of  
defendant)
- Upjohn v. Finch, 20  
USV Pharmaceutical Corp. v.  
Weinberger, 56, 325
- Various Articles of Drugs, United  
States v., 59  
Virginia Pharmacy Board v. Virginia  
Citizens Consumer Council, 279  
Virginia Uranium, Inc. v. Warren,  
602
- Washington v. Glucksberg, 90, 92  
Weinberger v. Bentax Pharm., 56,  
325, **336**  
Weinberger v. Hynson, Westcott &  
Dunning, Inc., 56, 324, **325**, 337,  
338  
Whitaker v. Thompson, **290**  
Wickard v. Filburn, 386  
Wiesenfeld Warehouse Co., United  
States v., 597  
Williamson v. Lee Optical of Okla.,  
Inc., 90  
Wisconsin v. Mitchell, 377  
Wong Wing Hang v. INS, 586  
Wyeth v. Levine, 603, **618**, 649



# Table of Principal Cases

---

---

62 Cases, More or Less, Each Containing 6 Jars of Jam v. United States, 340 U.S. 593 (1951)	183
Abbott Labs. v. Gardner, 387 U.S. 136 (1967)	48
Abigail Alliance v. Von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007) (en banc)	86
Alliance for Bio-Integrity v. Shalala, 92 F. Supp. 2d 166 (D.D.C. 2000)	234
Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011)	632
Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n of N.Y., 447 U.S. 557 (1980)	277
Chevron, U.S.A., Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837 (1984)	42
Fed. Sec. Adm'r v. Quaker Oats Co., 318 U.S. 218 (1943)	176
FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120 (2000)	533
FTC v. Actavis, Inc., 570 U.S. 136 (2013)	346
Gonzalez v. Raich, 545 U.S. 1 (2005)	384
Granholm v. Heald, 544 U.S. 460 (2005)	202
Heckler v. Chaney, 470 U.S. 821 (1985)	578
Hillsborough Cnty. v. Automated Med. Labs., Inc., 471 U.S. 707 (1985)	605
Hoffman-LaRoche, Inc. v. Weinberger, 425 F. Supp. 890 (D.D.C. 1975)	340
Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67 (2d. Cir. 1996)	219
Les v. Reilly, 968 F.2d 985 (1992)	229
Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996)	418
Merck Sharp & Dohme Corp. v. Albrecht, 139 S. Ct. 1668 (2019)	644
Nat'l Ass'n of Pharm. Mfrs. v. FDA, 637 F.2d 877 (2d Cir 1981)	54
Nat'l Nutr. Foods Ass'n v. Kennedy, 572 F.2d 377 (2d Cir. 1978)	249
Nat'l Nutr. Foods Ass'n v. Mathews, 557 F.2d 325 (2d Cir. 1977)	247
Pearson v. Shalala, 164 F.3d 650 (1999)	281
Pub. Citizen v. Young, 831 F.2d 1108 (D.C. Cir. 1987)	517
Riegel v. Medtronic, Inc., 552 U.S. 312 (2008)	611
Toilet Goods Ass'n v. Finch, 419 F.2d 21 (2d Cir. 1969)	509
United States v. 24 Bottles... Sterling Vinegar and Honey, 338 F.2d 157 (1964)	174
United States v. 298 Cases, etc., Ski Slide Brand Asparagus, etc., 88 F. Supp. 450 (D. Or. 1949)	170
United States v. An Article... Acu-Dot..., 483 F. Supp. 1311 (N.D. OH 1980)	411
United States v. An Article of Drug... Bacto-Unidisk..., 394 U.S. 784 (1969)	30

United States v. An Article . . . Sudden Change, 409 F.2d 734 (2d Cir. 1969)	497
United States v. Caronia, 703 F.3d 149 (2d Cir. 2012)	364
United States v. Generix Drug Corp., 460 U.S. 453 (1983)	343
United States v. Johnson, 221 U.S. 488 (1911)	310
United States v. Ninety-five Barrels (More or Less) Alleged Apple Cider Vinegar, 265 U.S. 438 (1924)	171
United States v. Park, 421 U.S. 658 (1975)	592
Weinberger v. Bentax Pharm., Inc., 412 U.S. 645 (1973)	336
Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609 (1973)	325
Whitaker v. Thompson, 248 F. Supp. 2d 1 (D.D.C. 2002)	290
Wyeth v. Levine, 555 U.S. 555 (2009)	618

# Table of Principal Federal Register Documents

---

1966-07-09 FDA Notice, Reports of Information for Drug Effectiveness	320
1970-05-08 FDA Final Rule, Hearing Regulations and Regulations Describing Scientific Content of Adequate and Well-Controlled Clinical Investigations	321
1972-01-05 FDA Proposed Rule, Proposal Establishing Rule-Making Procedures for Classification [of OTC Drugs]	359
1979-03-16 FDA Final Order, Vitamin and Mineral Products; Revocation of Regulations	256
1979-04-18 Dept. of Health, Education, and Welfare Notice, Protection of Human Subjects	69
1979-08-14 FDA Proposed Rule, Informed Consent	74
1980-05-30 FDA Final Rule, Protection of Human Subjects; Prisoners Used as Subjects in Research	78
1982-06-22 FDA Notice, Statement of Organization, Functions, and Delegations of Authority	462
1986-06-26 OSTP Policy Announcement, Coordinated Framework for the Regulation of Biotechnology	217
1987-03-19 FDA Final Rule, New Drug, Antibiotic, and Biologic Drug Product Regulations	126
1987-10-15 FDA Notice, Statement of Organization, Functions, and Delegations of Authority	463
1991-11-21 FDA Final Rule, Assignment of Agency Component for Review of Premarket Applications	440
1992-04-28 FDA Interim Rule, Medical Devices; Substantial Equivalence; 510(k) Summaries and 510(k) Statements; Class III Summaries; Confidentiality of Information	414
1997-07-29 FDA Final Rule, Human Tissue Intended for Transplantation	476
1997-09-23 FDA Final Rule, Premarket Notification for New Dietary Ingredients	262
1998-04-02 HHS Final Rule, Organ Procurement and Transplantation Network	485
1998-11-06 FDA Final Rule, Mutual Recognition of Pharmaceutical Good Manufacturing Practice Inspection Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports Between the United States and the European Community	660

1999-10-20 FDA Final Rule, Biological Products Regulated Under Section 351 of the Public Health Service Act; Implementation of Biologics License; Elimination of Establishment License and Product License	463
2001-01-19 Final Rule, Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Regulation and Listing	479
2003-06-26 FDA Notice, Drug and Biological Product Consolidation	465
2004-11-24 FDA Final Rule, Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement	482
2009-08-13 FDA Final Rule, Expanded Access to Investigational Drugs for Treatment Use	132
2010-03-19 FDA Final Rule, Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents	549
2011-01-06 FDA Proposed Rule, Tobacco Products, Exemptions from Substantial Equivalence Requirements	550
2011-07-05 FDA Final Rule, Tobacco Products, Exemptions from Substantial Equivalence Requirements	552
2013-01-22 FDA Final Rule, Current Good Manufacturing Practice Requirements for Combination Products	444
2015-11-27 FDA Final Rule, Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications	666
2015-11-27 FDA Final Rule, Foreign Supplier Verification Programs for Importers of Food for Humans and Animals	661
2015-12-02 USDA FSIS Final Rule, Mandatory Inspection of Fish of the Order Siluriformes and Products Derived from Such Fish	195
2016-05-10 FDA Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act	554, 560, 562
2016-12-20 Final Rule, Postmarket Safety Reporting for Combination Products	449
2017-01-09 FDA Final Rule, Clarification of When Products Made or Derived from Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding “Intended Uses”	451



# Table of Principal Guidance Documents

---

FDA, Guidance for Industry and FDA Staff: De Novo Classification Process (Evaluation of Automatic Class III Designation) (Oct. 2017)	424
FDA, Guidance for Industry and FDA Staff: Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Mar. 2020)	431
FDA, Guidance for Industry and FDA Staff: Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Mar. 2020)	425
FDA, Guidance for Industry: Color Additive Petitions—FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices (Jul. 2009)	514
FDA, Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims (Jan. 2009)	298
FDA, Guidance for Industry: FDA’s Implementation of Qualified Health Claims (May 2006)	295
FDA, Guidance for Industry: Investigational COVID-19 Convalescent Plasma (April 2020)	469



# Acknowledgments

---

This project developed over many years, and I accordingly owe many thanks. The first set goes to the students who have taken my food and drug classes over the years. From them, I learned the importance of organizing course materials in an approachable manner—something I hope I have managed to do here.

I am grateful for many years of summer research funding from Penn State Law, which allowed the project to develop in response to each year's class. A Fall 2019 sabbatical provided by Penn State University gave me time to restructure the book in a manner that, I hope, makes it more useful to the reader.

For excellent research assistance, I am grateful to Penn State Law students Kelly Allenspach, Rachel Awan, Michael Bond, Justin Fiorilli, Doug Fogle, Megan Green, Megan Janowiak, Sean Jorgensen, Kirill Lavinski, Chiao May Lee, Brandon Merritt, Rachel Sanders, Mike Schmidt, Corinne (Cori) Smith, Shaya Rubenstein, Megan Wells, and Jacob Wonn. For helpful comments on Chapter 4, I am grateful to Katrice Bridges Copeland, Steve Ostroff, and Chen-Sen (Samson) Wu.

Finally, I am grateful for the love and support of my dear family—Julia, Aaron, Keira, and Lydia. My gratitude to them goes beyond what words can express.



# Preface—About This Book

---

---

This book is intended for a law school survey course on food and drug regulation. It covers the Food and Drug Administration's (FDA's) regulation of food, food additives, dietary supplements, drugs, animal drugs, medical devices, combination products, biologics, HCT/Ps (human cells, tissues, and cellular and tissue-based products), cosmetics, color additives, and tobacco products. It also covers administrative procedure, regulation of research, FDA enforcement, federal preemption, and regulation of imports. It presents more limited material on related areas regulated primarily by other agencies.<sup>1</sup> In addition to covering this substantive material, the book will introduce you to the process of understanding a complex statute, its implementing regulations, and related enforcement policies.

The book's coverage is not intended to be comprehensive. Several existing books present treatise-level coverage and even those cannot cover FDA's regulatory programs comprehensively. This book instead focuses on core aspects of selected FDA regulatory programs in the areas of food and medical products.<sup>2</sup>

Food and drug regulation is primarily a statutory and regulatory subject. Accordingly, this book relies on a different set of documents and a different style of presentation than a typical casebook. The book emphasizes guided reading of the Federal Food, Drug, and Cosmetic Act, related statutes, FDA regulations, and Federal Register documents. Cases are presented primarily when they involve major issues of statutory interpretation, are historically significant, or are in one of the areas—such as federal preemption—where case law plays a major role in the overall regulatory scheme. Cases are also included where they provide a concise discussion of a regulatory program or a useful illustration of a concept.

This book is designed to work as a set with the accompanying Statutory & Regulatory Supplement (Supplement). The Supplement is available free, in PDF format, on this book's page of the Carolina Academic Press website.<sup>3</sup> The statutes and regulations in the Supplement have been aggressively edited, like the cases in a typical

---

1. These include USDA-regulated foods (meat, eggs, poultry, and fish of the order siluriformes (catfish and related species)), agricultural biotechnology, alcohol, controlled substances, and veterinary biologics.

2. The main categories the book does not address are animal food and feed, radiation-emitting products, and medical gases.

3. See <https://cap-press.com/books/isbn/9781531004453/Food-and-Drug-Regulation>.

law school casebook, to emphasize those aspects that are most important to a general understanding of the subject.

## Structure of the Book

The book is organized around the structure of the Federal Food, Drug, and Cosmetic Act of 1938 (FFDCA) and the relevant portion of the Public Health Services Act (PHSA).<sup>4</sup> This means that Chapter IV products (food, food additives, and dietary supplements), Chapter V products (drugs, animal drugs, medical devices, and combination products), and PHSA products (biologics and HCT/Ps) are each grouped together. The single-product-category chapters—Chapter VI (cosmetics), Chapter VII (color additives), and Chapter IX (tobacco products)—are then included in a final, catch-all group. Parts I, II, and VII of the book address cross-cutting issues, while Parts III, IV, V, and VI address the four groups of individual product categories. Part VIII contains the appendices.

Part I of the book introduces the basic structure of FDA and the FFDCA. Within Part I, Chapter 1 addresses the structure of the agency and the product categories set out in the FFDCA. Chapter 2 addresses administrative procedure. It contains material on administrative procedure generally and on administrative procedure specific to FDA.

Part II of the book addresses regulation of research, marketing authorization, and background regulatory requirements associated with marketing authorization. This Part emphasizes those aspects of research, marketing authorization, and background requirements that are similar across multiple product categories. Within Part II, Chapter 3 addresses regulation of research. It focuses on FDA regulation of human-subject research. Chapter 4 addresses marketing authorization. It contains material on pathways to market, designations, and access before market authorization. Chapter 5 addresses background requirements associated with marketing authorization. It contains information on production-process requirements, labeling requirements, establishment registration requirements, user fees, and postmarket requirements.

Part III of the book addresses those products regulated primarily under Chapter IV of the FFDCA. Chapter 6 addresses food, Chapter 7 addresses food additives, and Chapter 8 addresses dietary supplements. Chapter 9 does not address a single product category. Instead, it contains material on label claims for the two Chapter IV categories—food and dietary supplements—for which label-claim

---

4. Please note that this book uses: Roman numerals when referring to *parts of this book* (Part V); Arabic numerals when referring to *parts of the CFR* (21 C.F.R. Part 5); Arabic numerals when referring to *chapters of this book* (Chapter 5); and roman numerals when referring to *chapters of the FFDCA* (Chapter V).

issues arise. Label claims receive a separate chapter to avoid presenting duplicative material in the earlier chapters on food and dietary supplements.

Part IV of the book addresses those products regulated primarily under Chapter V of the FFDCA. Chapter 10 addresses drugs, Chapter 11 addresses animal drugs, Chapter 12 addresses medical devices, and Chapter 13 addresses combination products.

Part V of the book addresses those products regulated primarily under the PHSA. Chapter 14 addresses those aspects of biological products regulated primarily by the PHSA.<sup>5</sup> Chapter 15 addresses HCT/Ps.

Part VI of the book addresses those products regulated under the FFDCA Chapters VI, VII, and IX. Chapter 16 addresses cosmetics, Chapter 17 addresses color additives, and Chapter 18 addresses tobacco products.

Part VII returns to cross-cutting issues of the type addressed in Parts I and II. Chapter 19 addresses FDA enforcement, Chapter 20 addresses federal preemption, and Chapter 21 addresses regulation of imports.

Part VIII is an appendix recommending further reading. Its focus is on books rather than academic articles, with a particular emphasis on items available as audiobooks (a wonderful help to the busy lawyer during commuting or exercise). It includes both law-specific reading and material on scientific, technological, and industrial developments relevant to food and drug regulation.

For a description of the structure of individual chapters, see “Introduction to this Book” in Chapter 1, Part A.

## Citation Format and Editorial Approach

I have aggressively edited the documents that I have excerpted in this book. My goal in doing this is to emphasize those aspects of the excerpted documents that are most relevant to basic goal of this book: presenting an approachable overview of the basic structure of food and drug regulation.

Citations in this book conform generally to the 20th edition of *The Bluebook: A Uniform System of Citation*. Significant exceptions are the following:

I have cited Federal Register documents in a format that emphasizes the date of publication and type of document, rather than document title. I have done this for two reasons. First, these documents frequently contain cumbersome multipart titles that—despite their length—are of only limited value in describing the document’s

---

5. As you will see later, all products meeting the statutory definition of biological product, PHSA §351(i)(1), also meet the statutory definition of drug, FFDCA §201(g)(1). Accordingly, much of this chapter of the book is focused on the relationship between FDA’s biologics division (transferred from the National Institute of Health to FDA in the 1970s) and FDA’s drugs division.

content. Second, the administrative rulemaking process typically results in multiple documents with very similar titles. This book uses the format below, which I believe will help you distinguish more clearly between the different documents cited:

*[date of publication in YYYY-MM-DD format] [abbreviated agency name (FDA, USDA, EPA, etc.)] [type of document (notice, proposed rule, final rule, etc.)], [title or shortened title] [FR volume #] Fed. Reg. [FR page #]*

Within quoted original sources, the original citation format is retained except where I have determined that a modification will increase clarity or make the document more readable.

Also within quoted original sources, I have made the following omissions without any indication in the text:

- omitted most citations and footnotes, retaining only those that I believe will be of use to the reader (retained footnotes have their original numbering);
- omitted most quotation marks in situations where courts are simply quoting the language of prior judicial opinions as part of their own sentences (in the standard style of judicial opinion-writing);<sup>6</sup>
- modified the format of some retained citations to conform to the style of this book;
- replaced the use of a series of asterisks (common in older documents) with the modern use of three-dot or four-dot ellipses, as appropriate;
- omitted text from the part of an excerpted document that precedes the quoted language.

Where I have omitted text from a quoted source, I have used three-dot ellipses to indicate omissions of less than a sentence and four-dot ellipses to indicate omissions of a full sentence or more.

Within quotations and excerpts referencing the FFDCA or the PHSA, I have replaced references to U.S. Code section numbers with references to the corresponding FFDCA section numbers, following the standard approach in this book. Where I have done this, I have used the notation “[FFDCA §]” to indicate the change.

One final editorial convention bears emphasis. Both the FFDCA and the PHSA are phrased in terms of authorities granted to, and obligations imposed upon, “the Secretary”—meaning the Secretary of Health and Human Services—rather than FDA. See FFDCA §201(d). The Secretary of Health and Human Services, however, has delegated nearly all of the authority to administer these statutes to the Commissioner of Food and Drugs. See FDA STAFF MANUAL GUIDES, VOLUME

---

6. This is necessary to facilitate omission of citations to the quoted documents, with the aim of making those excerpts more readable. I have done this only in excerpts, not within the text of the book. Even within excerpts, I have never intentionally omitted quotation marks from sources other than judicial opinions.



II—DELEGATIONS OF AUTHORITY § 1410.10 (Effective Date: August 26, 2016). To make textual descriptions of statutory language more readable, I have generally substituted “FDA” for “the Secretary” in describing the language of the statute. This means that:

- In places where the FFDCA grants “the Secretary” authority to take a particular action, I typically describe it as granting “FDA” such authority.
- In places where the FFDCA requires “the Secretary” to take some action, I typically describe it as requiring “FDA” to take such action.

